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Background and Purpose—Factor V Leiden and a prothrombin gene variant, G20210A, are mutations associated with a
thrombotic risk. The aim of our study was to assess whether these mutations increase the risk of stroke in women under
45 years of age.
Methods—We conducted a case-control study in westem Washington State. Case patients werfe women aged 18 to 44 years
with a first stroke (n=106). Control subjects were women without stroke recruited from the same region by use of
random-digit telephone dialing (n=391). All were interviewed and provided blood specimens, which were genotyped for
these mutations.
Results—Factor V Leiden was found in 0.9% of case patients, a single patient with a subarachnoid hemorrhagc, and in 4.1%
of control subjects. The ödds ratio (OR.) for any stroke was 0.2 (95% confidence interval [CI], 0.03 to 1.7). The
prothrombin variant was found in 1.9% of case patients, l with a venous stroke and l with an ischemic stroke, and in 1.6%
of control subjects. The OR for any stroke was 1.48 (95% CI, 0.14 to 9.17). ORs for stroke types were also not statistically
significant.
Condusions—In this study, neither factor.V Leiden nor the prothrombin variant (G20210A) was an important risk factor for
stroke in young women. In this setting, scceening for these mutations cannot be recommended. Unanswered by this study
is whether screening would be useful in select patients, such äs those with a strong family history of thrombophilia or those
with venous strokes. (Stroke. 1998;29:577-580.)
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Factor V Leiden and a recendy described variant of theprodirombin gene are both clotdng factor mutations that
are associated with an increased tendency for venous throm-
bosis.1"4 Pactor V Leiden, is a single-point mutation on the
factor V gene in which adenine is substituted for guanine at
nucleoüde position 1691. The mutation rcsults in a change in
die factor V molecule where activated protein C would
nocmally cleave and partially inactivate factor V. The result is
a resistance to activated protein C.12 In a recendy described
prodirombin variant, adenine is substituted for guanine at
Position 20210 (G20210A) in the noncoding 3' terminal end
of the prothrombin gene.3'1 This variant is associated widi
increased prothrombin levels. Although the prothrombin mol-
ecule is normal, its expression is not. Factor V Leiden is a
relatively common hereditary abnormality widi a 3% to 5%
prevalence of heterozygous carriers,2 whereas the prothrombm
vanant, at 1% to 3%, is less prcvalent.3·'1 Although ehe associ-
ation of these mutations with venous thrombosis has been
demonstrated,1"4 the association with arterial disease has not. As
recenüy reviewed, the studies have not been consistent with
respect to an association of factor V Leiden with coronary
artery disease and myocardial infarction,5 and the studies of the
prothrombin variant are limited.6 Ahhough Information on the
prothrombin variant in patients widi ischemic stroke is limited
to a single negative feport,7 many reports' have concemed
factor V Leiden and have not found the risk of ischemic stroke
to be elevated consistendy.*"** Using data collected äs part of a
recent populadon-based case-control study,35 we examined the
associacion of stroke in young women with these two
mutations.
Subjects and Methods
We conducted a population-based case-control study of myocirdia]
infarcrion and stroke among women aged 18 to 44 years residing in
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King, Pierce, and Snohomish counties, three conciguous counties in
western Washington state. The study was designed to evaluate the risk
of cardiovascular and cerebrovasculat diseases with the use of oral
contracepaves.35 Genotyping for factor V Leiden and the prothrombin
variant were perfotmed on a subsec of case patients and control
subjects. Associations of myocardial infarction wich fäctor V Leiden
was the focus of one previous study5 and with the prothrombin
variant, another.* This report is Hmited to stroke. As detailed previ-
oush/,55 ehgible case patients were fcee of prior cardiovascular and
cerebrovascular diseases, and diagnosis was made between July l,
199J, and Febtuary 28, 1995, of their first fetal or nonfätal stroke.
Stroke was deSned by evidence of new focal neurological deficic
lasting morc than 24 houcs or resulting in death in less than 24 hours.
Strokes wcrc classified äs venous or arteriaL Arterial scrokes were
fiirrher clraified äs hemorrhagic, ischetnic, or other. For a stroke to be
classified äs hemorrhagic, imaging studies or lumbar puncture had to
provide evidence of blood in the brain parenchyma, the subarachnoid
space, or both. Arterial dissections that resulted in stroke were
included in the "other" category.
Smdy personnel abstracted diagnosüc inforrnation ftom hospital
records. Resulß of brain imaging studies were available for 92% of the
case patients. The study neurologist (W.T.L.) reviewcd the hospital
records of all potential case patiencs to conGrm die diagnosis and to
classify the type of stroke. We identified 249 eligible case patients
thtough the review of discharge diagnoses &om all hospitals widün the
stndy region; 198 were living ac the nme we initiated recruitment
activities, and 149 were recruited and interviewed.
We used random-digit telephone dialing to identicy a sample of
women aged 18 to 44 years who were resident* of King, Pierce, or
Snohomish county during the time period of the study, äs described
previously.35 Concrol subjects were frequency matchcd to case patiencs
by age. Of the 684 eligible women, 526 were recnnted and
interviewed.
Participating case patients and control subjects were interviewcd in
person regarding cardiovascular and cercbrovascuhr risk fäctors. In
addition, ehe Interviewer obtained 30 mL nonfasting venous blood in
EDTA-treated evacuated tubes (mm the antecubital vein. Samples
•were collectcd frorn 106 of 149 participating case patients (71%) and
391 of 526 participating control subjects (74%) who were interviewed.
We compared the women who were interviewed and gave blood with
thosc who were interviewed buc declined venipuncture and found no
important difierences (data not shown). Blood specimens were geno-
typed for factor V Leiden and the prochrombin variant with use of
published methods.5·* Briefly, die presence of factor V Imitation (1691,
G-to-A replacement) was inferred firom the loss of an Mnl l restricdon
site5 and the presence of the prothrombin variant (20210, G-to-A
replacement) was confirmed by the presence of a HiVuflU restricdon
site in an A allele-specific polymerase cham reaction fragment.6 These
determinadons were accomplished without knowledge of whether the
speamen came from a case parient or control subject. Determmations
for fäctor V Leiden were available in 105 of the 106 case padents (99%)
and 388 of the 391 control subjects (99%) and for the prothrombin
variant m 105 case patients (99%) and 382 control subjects (98%).
Altogether, genotyping for bodi m'utadons were available in 381
concrol subjects (97%) and 104 case subjects <98%).
The associacion of diese two mutations widi strofce was examined
by the calculation of the odds rado (OR), äs an esomate of relative
nsk, and 95% confidence interval (CI).M The study was ipproved by
the Human Subjects Review Committcc at the University of Wash-
ington, and thosc who participated m the study all prowded mformed
conscm.
Results
In the 106 case paaents with blood specimens available for
analyses, 2 strokes were venous and 104 were arterial (of which
54 were hemorrhagic, 41 were ischemic, and 9 were dissec-
tions) The l patient for whom the factor V Leiden determi-
nation was missing had an ischemic stroke, and the l for whom
the prothrombin variant determinauon was missing had an
arterial dissection. The mean age of the 106 case patients was
36.6 years (ränge, 18 to 44 years), with 88 (83%) being white.
6 (6%) black, and 12(11%) classified äs other. The mean age of
the 391 control subjects was 37.7 years (ränge, 19 to 44 years),
with 350 (90%) being white, 9 (2%) black, and 32 (8%) other.
Sixteen of the 388 control subjects (4.1%) but only l of the 105
case patients (0.9%) had the factor V Leiden mutation. The
patient was a 33-year-old white wo man with a subarachnoid
hemorrhage who had treated hypertension, diabetes, and
obesity. The OR. for any stroke was 0.2 (95% Cl, 0.03 to 1.7);
for hemorrhagic stroke, 0.4 (95% CI, 0.1 to 3.4); and for
ischemic stroke, 0 (95% CI, O'to 2.5). All of these CIs are broad
and include 1.
Six of the 382 control subjects (1.6%) and 2 of the 105 case
patients (1.9%) had the prothrombin variant. One, a 33-year-
old white woman who was using oral contraceptives at the
time of her event, was free of other 'recognized stroke risk
factors and had a venous stroke. The other was a 32-year old
white woman with long-standing hypertension and epilepsy
who had an ischemic stroke 11 days postpartum. Evaluation
failed to suggest a right-to4eft shunt through the heart, and
venous thrombosis of the lower extremities was not clinically
evident. The OR for any stroke was 1.2 (95% CI, 0.1 to 6.9);
for hemorrhagic stroke, 0 (95% CI, 0.0 to 6.8); and for
ischemic stroke, 1.6 (95% CI, 0.03 to 13.4). Again, these CIs
are broad and include 1.
Carriership of either mutation was found in 22 of 382
control subjects (5.8%) and 3 of 104 case patients (2.9%). The
OR for any stroke was 0.49 (95% CI, 0.09 to 1.7). No one
carried both mutations, although l control subject who had
factor V Leiden and who was included among the 22 control
subjects above could not be genotyped for the prothrombin
variant. None of the 3 case patients with one of these
mutations had a fätnily history of stroke, and the only case
patient with the factor V Leiden (who sufFered a subarachnoid
hemorrhage) had a family history of myocardial infarction.
This patient's brother was reported to have sufFered a myocar-
dial infarction at age 27 years. Of the 22 control subjects with
either of the mutadons, 3 (13.6%) had a family history of
stroke, 7 (31.8%) had a family history of myocardial infarction,
and 10 (45.4%) had a family history of either stroke or
myocardial infarction.
Discussion
Our inability to find a strong association between stroke and fäctor
V Leiden is consistent with the findings of many previous
studies."1"'34 We also were unable to find an association between
stroke and the prothrombin variant with adenine substituted for
guanine at position 20210 (G20210A), consistent with a previous
report' In the studies of fäctor V Leiden, which havc included
diöcrent types of patients with stroke but almosc exclusively
ischemic stroke, 0 to 13.8% of patients carried factor V Leiden. In ·
the current study, none of the 40 women with ischemic strokes
had factor V Leiden (95% CI derived from the binomial distri-
bution, 0 to 8.8%). Considering prior reports on series of padents
with stroke »-».ifc'WWiÄisJMH» and the results of ι1ώ study for
ischemic stroke, we calculated that 73 of 1610 stroke patients
(4.5%) who have been genotyped carry fäctor V Leiden, similar to
the 3% to 5% reported fbr the general population.2 The associa-
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rion between iäctor V Leiden and hetnmorrhagic stroke was also
not statistically significant (OR, 0.4; 95% CI, 0.1 to 3.4).
^c had only two womcn with venous strokes in the current
study. Neither had iäctor V Leiden, but one had the prothrom-
bin variant. We had too fe.w patients with venous strokes to
reach any conclusions about associations, but other reports
have described patients with venous strokes and fäctor · V
Leiden.37"" In these series, 11% to 21% of patients with
cerebral venous thrombosis have carried fäctor V Leiden.40·43·46
More patients will need to be studied before a conclusion can
be reached about a possible association between the prothrom-
bin variant and venous stroke.
One potential problem in the current study arises because
blood specimens were obtained at the time of interview.
Patients who died or were disabled äs a consequence of their
stroke were not represented among those who wete studied. If
these mutatibns were associated with more severe strokes and
consequendy death or disability, we would be underestimating
the efiect of these mutations with this study design. We cannot
exclude such a possibility in tbis study. Eleven patients with
ischemic strokes who were eligible for this study did not
participate because of death or disability. If we assume that all.
were carriers of the mutations, the recalculated OR is 3.0 for
fäctor V Leiden and 9.9 for the prothrombin variant. Such
extreme assumptions are unlikely to hold, but these ORs give
an idea of what could be possible.
Other studies that have also been unable to identify an
association between fäctor V Leiden and stroke have sufieied
from the same potential problem because blood samples were
collected some dme afier the acute event.12·18·13 Nonetheless, in
one study in which blood samples were collected at presenta-
tion, 15 of 348 patients (4.3%) with an ischemic infärction
carried fäctor V Leiden.11 In addition, the mutation was not
related to mortality at l or 3 months after the initial stroke.M In
another study in which patients provided blood within 7 days
of their stroke, only 4 of 161 (2.5%) carried the mutation.27
Whedier patients who were unable to provide consent were
excluded from these two studies is unclear. Finally, in the
Physicians' Health Study,16 209 men for whom blood samples
•were available from baseline went on to experience a stroke
during follow-up. Nine of the 209 (4.3%) had the mutation, a
Bgure somewhat lower than the 6% found in men who
remained free of vascukr disease. Although the results of these
studies may not entirely apply to women under 45 years of age
with stroke who were enrolled in the current study, these
results suggest thac exclusion of women with severe strokes was
unlikely to have had a major effect on our öndings.
The current study included too few Hispanic and black
patients to address the question of ethnic or racial variations. In
one study,22 although some Hispanic patients with ischemic
stroke had resistance to activated protein C, none of the them
had fäctor V Leiden nor did any of the Hispanic controls'. Also
of note, fäctor V Leiden does not seem to play an important·
role among black patients with sickle cell disease. Only l of 82
such patients (1.2%) had fäctor V Leiden, and none of ehe 15
witli a history of stroke had the mutation.12
The current study and others do not support the routine
scceening for these mutations in patients with ischemic strokes.
Unanswered by this study is whether scceening would be more
useful in select patients, such äs those venous strokes. Other
investigators have suggested that such select groups rnay
include patients with an ischemic stroke combined with one of
the following features: a strong family history of thrombophil-
ia,17 pregnancy and puerperium,15·24 childhood,23·2* an angto-
graphic complication,31 oral contraceptive use and antiphos-
pholipid syndrome,22 paradoxical embolus with deep-vein
thrombosis and patent foramen ovale,0 migraine," and young
age without any risk fäctors.9·10 Given the· relative rarity of such
ischemic strokes; the Utility of screening for these two muta-
tions in these settings will remain difficult to define.
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